• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The anti ‑dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression.
The anti‑dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression. Mol Med Rep. 2016 Jul 13; Authors: Bryan-Marrugo OL, Arellanos-Soto D, Rojas-Martinez A, Barrera-Saldaña H, Ramos-Jimenez J, Vidaltamayo R, Rivas-Estilla AM Abstract Dengue virus (DENV) susceptibility to cholesterol depleting treatments has been previously reported. There are numerous questions regarding how DENV seizes cellular machinery and cholesterol to improve viral production and the effect of cholesterol sequestering agents on the cellular antiviral response. The aim of...
Source: Molecular Medicine Reports - July 21, 2016 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism
Despite significant reduction of cardiovascular events by statin treatment, substantial residual risk persists, driving emerging needs for the development of new therapies. We identified a novel cholesteryl ester transfer protein (CETP) inhibitor, K-312, that raises HDL and lowers LDL cholesterol levels in animals. K-312 also suppresses hepatocyte expression of proprotein convertase subtilisin/kexin 9 (PCSK9), a molecule that increases LDL cholesterol. We explored the underlying mechanism for the reduction of PCSK9 expression by K-312. K-312 inhibited in vitro human plasma CETP activity (IC50; 0.06 μM). Administration o...
Source: AJP: Endocrinology and Metabolism - July 15, 2015 Category: Endocrinology Authors: Miyosawa, K., Watanabe, Y., Murakami, K., Murakami, T., Shibata, H., Iwashita, M., Yamazaki, H., Yamazaki, K., Ohgiya, T., Shibuya, K., Mizuno, K., Tanabe, S., Singh, S. A., Aikawa, M. Tags: Articles Source Type: research

New CETP Inhibitor K-312 Reduces PCSK9 Expression: A Potential Effect on LDL Cholesterol Metabolism.
Abstract Despite significant reduction of cardiovascular events by statin treatment, substantial residual risk persists, driving emerging needs for the development of new therapies. We identified a novel cholesteryl ester transfer protein (CETP) inhibitor, K-312, that raises HDL- and lowers LDL-cholesterol levels in animals. K-312 also suppresses hepatocyte expression of proprotein convertase subtilisin/kexin 9 (PCSK9), a molecule that increases LDL cholesterol. We explored the underlying mechanism for the reduction of PCSK9 expression by K-312. K-312 inhibited in vitro human plasma CETP activity (IC50: 0.06 μM)....
Source: Am J Physiol Endocri... - May 26, 2015 Category: Endocrinology Authors: Miyosawa K, Watanabe Y, Murakami K, Murakami T, Shibata H, Iwashita M, Yamazaki H, Yamazaki K, Ohgiya T, Shibuya K, Mizuno K, Tanabe S, Singh SA, Aikawa M Tags: Am J Physiol Endocrinol Metab Source Type: research